Resistance management of Pertuzumab

The HER2-targeting antibody Pertuzumab and the HER2-directed antibody-drug conjugate trastuzumab are used to treat HER2-overexpressing breast cancer. Pertuzumab shows good efficacy in most patients, but sometimes resistance (acquired resistance) may occur, and these treatments eventually become ineffective, so there is an urgent need for alternative therapies.

In the study, treatment with trastuzumab and pertuzumab orT-DM1 initially induced tumor regression in NCI-N87 xenografts. However, tumor regrowth during treatment indicates a loss of drug effectiveness. HER2-HER3 phosphorylation is preserved in tumors with acquired resistance to trastuzumab and pertuzumab or T-DM1. Switching to TAS0728, a small molecule, irreversible, selective HER2 kinase inhibitor, resulted in significant antitumor effects associated with inhibition of HER2-HER3 signaling. If a patient develops resistance to pertuzumab, he should communicate with his doctor in a timely manner and adjust his medication.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.